Literature DB >> 1892201

Maternal plasma level of endothelin is increased in preeclampsia.

A Nova1, B M Sibai, J R Barton, B M Mercer, M D Mitchell.   

Abstract

Endothelin is a potent vasoconstrictor that is reportedly increased in conditions characterized by endothelial damage. Maternal plasma endothelin levels were compared between 27 women with preeclampsia (23 without and 4 with the hemolysis, elevated liver enzymes, and low platelet count syndrome) and 14 women with normotensive pregnancies. The mean +/- SEM plasma endothelin values were significantly higher in patients with preeclampsia uncomplicated by the hemolysis, elevated liver enzymes, and low platelet count syndrome (5.48 +/- 0.30 fmol/ml vs 3.86 +/- 0.28, p less than 0.001). In addition, the preeclamptic group with the hemolysis, elevated liver enzymes, and low platelet count syndrome had significantly higher endothelin levels than those without the syndrome (8.30 +/- 1.62 fmol/ml vs 5.48 +/- 0.30, p less than 0.05). There was no correlation between plasma endothelin values and either systolic or diastolic blood pressure. We conclude that plasma endothelin levels are significantly increased in women with preeclampsia and particularly in those with the hemolysis, elevated liver enzymes, and low platelet count syndrome, suggesting an association with widespread endothelial damage.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1892201     DOI: 10.1016/0002-9378(91)90317-k

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  31 in total

Review 1.  Pathophysiology and maternal biologic markers of preeclampsia.

Authors:  Jacques Massé; Yves Giguère; Abdelaziz Kharfi; Joël Girouard; Jean-Claude Forest
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

2.  Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2012-08

3.  The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2010-04

4.  The significance of endothelin in platelet-activating factor-induced fetal growth restriction.

Authors:  Mark G Neerhof; Saira Khan; Sylvia Synowiec; Xiao-Wu Qu; Larry G Thaete
Journal:  Reprod Sci       Date:  2012-04-25       Impact factor: 3.060

Review 5.  Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia.

Authors:  Babbette D LaMarca; Jeffery Gilbert; Joey P Granger
Journal:  Hypertension       Date:  2008-02-07       Impact factor: 10.190

Review 6.  Sleep Disordered Breathing, a Novel, Modifiable Risk Factor for Hypertensive Disorders of Pregnancy.

Authors:  Laura Sanapo; Margaret H Bublitz; Ghada Bourjeily
Journal:  Curr Hypertens Rep       Date:  2020-03-12       Impact factor: 5.369

Review 7.  The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia.

Authors:  Langeza Saleh; Koen Verdonk; Willy Visser; Anton H van den Meiracker; A H Jan Danser
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-01-10

8.  Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia.

Authors:  Cissy Chenyi Zhou; Roxanna A Irani; Yingbo Dai; Sean C Blackwell; M John Hicks; Susan M Ramin; Rodney E Kellems; Yang Xia
Journal:  J Immunol       Date:  2011-04-11       Impact factor: 5.422

9.  Differential localization of endothelin ETA and ETB binding sites in human placenta.

Authors:  R A Rutherford; J Wharton; A McCarthy; L Gordon; M H Sullivan; M G Elder; J M Polak
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

10.  Endothelial microparticles and the antiangiogenic state in preeclampsia and the postpartum period.

Authors:  Loren Petrozella; Mala Mahendroo; Brenda Timmons; Scott Roberts; Donald McIntire; James M Alexander
Journal:  Am J Obstet Gynecol       Date:  2012-06-11       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.